-

Thermo Fisher Scientific’s Clinical Research Business Named Clinical Research Company of the Year for Third Consecutive Year

WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD clinical research business of Thermo Fisher Scientific has been named Clinical Research Company of the Year at the 2022 PharmaTimes Clinical Researcher of the Year International competition held recently in London.

In addition to the business winning the highest honor again this year, 50 clinical researchers from the company were named finalists within all nine eligible team and individual competition categories.

“For the third year in a row, our colleagues have made their presence known by winning multiple recognitions, including the top title, in this highly regarded competition,” said Amber Lee, senior vice president, clinical operations, clinical research, Thermo Fisher Scientific. “The unwavering dedication, expertise and passion our colleagues put on display at the competition are the same qualities they apply every day to our customers’ vital research initiatives. We believe in sustaining a great culture and providing our colleagues with challenging opportunities for professional growth. This, in turn, supports our ability to recruit, develop and retain top talent to serve our customers.”

The business’ award-winning training and development programs, such as CRA Academy, are a key component in strengthening employees’ skills. The academy guides clinical research associates as they gain real-time work experience with effective training and formal academy-based learning. To date, more than 1,000 professionals have graduated from the program.

The Clinical Researcher of the Year Awards competition, hosted by PharmaTimes, consists of a rigorous series of assessments, including a three-stage competition, where participants give presentations before a panel of experienced industry judges. The event was created to provide clinical research professionals an opportunity to benchmark their skills against their peers in a program of competency-based exercises developed through cross-industry collaboration.

Colleagues from Thermo Fisher’s clinical research business won gold in the Aspiring Clinical Research Associate (CRA) category, silver in the CRA category, silver and bronze in the In-House CRA category, silver in the Team Leader category, bronze in the Clinical Team category, gold and bronze in the Start Up-Singles category, as well as gold and silver in the Start-Up Team category.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Contacts

Media Contact Information:
Nadine Maeser
Clinical Research, Thermo Fisher Scientific
(910) 558-4779
nadine.maeser@ppd.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
Thermo Fisher Scientific’s PPD clinical research business has been named Clinical Research Company of the Year for the third consecutive year.
Release Versions

Contacts

Media Contact Information:
Nadine Maeser
Clinical Research, Thermo Fisher Scientific
(910) 558-4779
nadine.maeser@ppd.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom